PCN89 A Cost-Effectiveness Analysis of Atezolizumab in Combination with Carboplatin and Etoposide in Patients with Untreated Extensive-Stage Small Cell Lung Cancer
Dec 1, 2020, 00:00
10.1016/j.jval.2020.08.226
https://www.valueinhealthjournal.com/article/S1098-3015(20)32482-7/fulltext
Title :
PCN89 A Cost-Effectiveness Analysis of Atezolizumab in Combination with Carboplatin and Etoposide in Patients with Untreated Extensive-Stage Small Cell Lung Cancer
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(20)32482-7&doi=10.1016/j.jval.2020.08.226
First page :
Section Title :
Open access? :
No
Section Order :
10175